Pfizer pens $500M+ deal with Enodia to destroy disease-causing proteins

Summary

Pfizer has signed a collaboration deal valued at $500M+ with Enodia Therapeutics to develop small-molecule drugs targeting pathogenic protein elimination. The partnership follows Pfizer's venture arm co-leading Enodia's $25 million seed round in January.